

Hazaribagh Ranchi Expressway Limited

June 08, 2021

Ratings

| Instruments | Amount (Rs. crore) | Rating ⁴ | Rating Action | |
|---|------------------------|--|--|--|
| Senior Non-Convertible Debentures (NCDs) – Series A | 458.00 | CARE D; ISSUER NOT COOPERATING* (Single D ISSUER NOT COOPERATING*) | Rating continues to remain under ISSUER NOT COOPERATING category | |
| Subordinate Non-Convertible Debentures (NCDs) – Series B | 143.00 | CARE D; ISSUER NOT COOPERATING* (Single D ISSUER NOT COOPERATING*) | Rating continues to remain under ISSUER NOT COOPERATING category | |
| Total Long-Term Instruments | 601.00 (Rs. Six Hur | ndred One Crore Only) | | |

Details of instruments in Annexure-1

Detailed Rationale & Key Rating Drivers

Hazaribagh Ranchi Expressway Limited (HREL) has not serviced its debt obligations since April 2019. The same has been confirmed by the Debenture Trustee to CARE, as part of CARE's due diligence and from the publication made by HREL on NSE. CARE has also received monthly NDS till May 2021, stating defaults in the debt servicing.

CARE had, vide its press release dated April 4, 2019 and April 16, 2019, placed the ratings of Hazaribagh Ranchi Expressway Limited (HREL) under the 'issuer non-cooperating' category as HREL had not paid the surveillance fees for the rating exercise as agreed to in its Rating Agreement. HREL continues to be non-cooperative despite repeated requests for submission of information through phone calls and e-mails dated May 9, 2021 and May 29, 2021, among others.

In line with the extant SEBI guidelines, CARE has reviewed the rating on the basis of the best available information.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating(s).

Detailed description of the key rating drivers

Please refer to last PR date June 23, 2020

Analytical approach: Standalone

Applicable Criteria

Policy in Respect of Non-cooperation by Issuer CARE's Policy on Recognition of Default

Criteria on assigning 'outlook' and 'credit watch' to Credit Ratings

Rating Methodology: Factoring Linkages in Ratings

Financial Ratios - Non-Financial Sector

Rating Methodology - Infrastructure Sector

About the Company

Hazaribagh-Ranchi Expressway Limited was incorporated on March 19, 2009, as a Special Purpose Vehicle promoted by ITNL; holding 99.99% and Punj Lloyd Limited holding the balance. The company entered into a Concession Agreement (CA) with National Highway Authority of India - NHAI (rated 'CARE AAA; Stable') on October 8, 2009 for the purpose of designing, constructing and maintaining the 4-laning of the Hazaribagh - Ranchi section of NH-33 from 40.50 km to 114.00 km in Jharkhand on a Build Operate Transfer (BOT) - Annuity basis. The concession period is for 18 years commencing from the appointed date, including construction period of 910 days. HREL achieved provisional completion on September 15, 2012 and received first annuity of Rs.64.08 crore (semi-annual) in July 2013. The project was completed ahead of time and Commercial Operation Date (COD) was achieved 134 days ahead of scheduled project completion which entitled HREL to receive the early completion bonus of Rs.47.00 crore which was received in FY14. HREL completed the construction of project stretch in August 2014 and received the project completion certificate in April 2015.

¹Complete definitions of the ratings assigned are available at <u>www.careratings.com</u> and in other CARE publications

^{*}Issuer did not cooperate; Based on best available information

Press Release



| Brief Financials (Rs. crore) | FY19 (A) | FY20 (A) |
|------------------------------|----------|----------|
| Total operating income | 91.95 | 99.85 |
| PBILDT | -121.54 | 73.87 |
| PAT | -165.40 | 73.85 |
| Overall gearing (times) | NM | NM |
| Interest coverage (times) | NM | NM |

A: Audited; NM: Not Meaningful

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Rating History for last three years: Please refer Annexure-2

Covenants of rated instrument: Not Applicable

Complexity level of various instruments rated for this company: Annexure 3

Annexure-1: Details of Instruments

| Name of the Instrument | ISINs | Date of Issuance | Coupon Rate | Maturity Date | Size of the Issue (Rs. crore) | Rating assigned along with Rating Outlook |
|---|--|----------------------|----------------|-------------------|-------------------------------------|---|
| Debentures- Non Convertible Debentures | INE526S07056; INE526S07064; INE526S07072; INE526S07080; INE526S07098; INE526S07106; INE526S07114; INE526S07122; INE526S07130; INE526S07148; INE526S07155; INE526S07163; INE526S07171; INE526S07189; INE526S07197; INE526S07205; INE526S07213 | February 14, 2017 | 8.50 | April 14, 2027 | 458.00 | CARE D; ISSUER NOT COOPERATING* |
| Debentures- Non Convertible Debentures | INE526S07254; INE526S07262; INE526S07270; INE526S07288; INE526S07296; INE526S07304; INE526S07312; INE526S07320; INE526S07338; INE526S07346; INE526S07353; INE526S07361; INE526S07379; INE526S07387; INE526S07395; INE526S07403; INE526S07411 | February 14, 2017 | 8.75 | April 14, 2027 | 143.00 | CARE D; ISSUER NOT COOPERATING* |

^{*}Issuer did not cooperate; Based on best available information



| | | Current Ratings | | | Rating history | | | |
|------------|---|-----------------|--------------------------------------|---------------------------------------|--|--|---|--|
| Sr. No. | Name of the Instrument | Туре | Amount Outstanding (Rs. crore) | Rating | Date(s) & Rating(s) assigned in 2021- 2022 | Date(s) & Rating(s) assigned in 2020-2021 | Date(s) & Rating(s) assigned in 2019-2020 | Date(s) & Rating(s) assigned in 2018-2019 |
| 1. | Debentures- Non Convertible Debentures | LT | 458.00 | CARE D; ISSUER NOT COOPERATING* | - | 1)CARE D; ISSUER NOT COOPERATING * (23-Jun-20) | 1)CARE D; ISSUER NOT COOPERATING * (16-Apr-19) 2)CARE C (CWN); ISSUER NOT COOPERATING * (04-Apr-19) | 1)CARE C (CWN) (11-Mar- 19) 2)CARE BB (SO) (CWN) (30-Jan-19) 3)CARE AAA (SO) (CWN) (24-Oct-18) 4)CARE AAA (SO) (CWN) (05-Oct-18) |
| 2. | Debentures- Non Convertible Debentures | LT | 143.00 | CARE D; ISSUER NOT COOPERATING* | - | 1)CARE D; ISSUER NOT COOPERATING * (23-Jun-20) | 1)CARE D; ISSUER NOT COOPERATING * (16-Apr-19) 2)CARE C (CWN); ISSUER NOT COOPERATING * (04-Apr-19) | 1)CARE C (CWN) (11-Mar- 19) 2)CARE BB (SO) (CWN) (30-Jan-19) 3)CARE AAA (SO) (CWN) (24-Oct-18) 4)CARE AAA (SO) (CWN) (05-Oct-18) |

^{*}Issuer did not cooperate; Based on best available information

Annexure 3: Complexity level of various instruments rated for this company

| Sr. No. | Name of the Instrument | Complexity Level |
|---------|---------------------------------------|------------------|
| 1. | Debentures-Non Convertible Debentures | Simple |

Note on complexity levels of the rated instrument: CARE has classified instruments rated by it on the basis of complexity. This classification is available at www.careratings.com. Investors/market intermediaries/regulators or others are welcome to write to care@careratings.com for any clarifications.

Press Release



Contact us

Media Contact

Mradul Mishra
Contact no. – +91-22-6754 3573
Email ID – mradul.mishra@careratings.com

Analyst Contact

Group Head Name – Rajashree Murkute
Group Head Contact no.- +91-22-6837 4474
Group Head Fmail ID, rajashree murkute@carer

Group Head Email ID- rajashree.murkute@careratings.com

Relationship Contact

Name: Saikat Roy

Contact no.: +91-22-6754 3404 Email ID : saikat.roy@careratings.com

About CARE Ratings:

CARE Ratings commenced operations in April 1993 and over two decades, it has established itself as one of the leading credit rating agencies in India. CARE is registered with the Securities and Exchange Board of India (SEBI) and also recognized as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). CARE Ratings is proud of its rightful place in the Indian capital market built around investor confidence. CARE Ratings provides the entire spectrum of credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. Our rating and grading service offerings leverage our domain and analytical expertise backed by the methodologies congruent with the international best practices.

Disclaimer

CARE's ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE's ratings do not convey suitability or price for the investor. CARE's ratings do not constitute an audit on the rated entity. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE or its subsidiaries/associates may also have other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating /outlook assigned by CARE is, inter-alia, based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors. CARE is not responsible for any errors and states that it has no financial liability whatsoever to the users of CARE's rating. Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.

^{**}For detailed Rationale Report and subscription information, please contact us at www.careratings.com